2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
- PMID: 31504418
- DOI: 10.1093/eurheartj/ehz455
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
Erratum in
-
Corrigendum to: 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.Eur Heart J. 2020 Nov 21;41(44):4255. doi: 10.1093/eurheartj/ehz826. Eur Heart J. 2020. PMID: 31837134 No abstract available.
Keywords: Guidelines; apolipoprotein B; cholesterol; dyslipidaemias; familial hypercholesterolaemia; high-density lipoproteins; lipoprotein remnants; lipoprotein(a); low-density lipoproteins; total cardiovascular risk; treatment (adherence); treatment (drugs); treatment (lifestyle); triglycerides; very low-density lipoproteins.
Comment in
-
Do we need a redefinition of the cardiovascular risk categories used in the 2019 ESC/EAS guidelines on dyslipidaemias?Eur Heart J. 2020 Jun 21;41(24):2332. doi: 10.1093/eurheartj/ehz940. Eur Heart J. 2020. PMID: 32031600 No abstract available.
-
A clinical perspective on the 2019 ESC/EAS guidelines for the management of dyslipidaemias: PCSK-9 inhibitors for all?Eur Heart J. 2020 Jun 21;41(24):2331. doi: 10.1093/eurheartj/ehaa005. Eur Heart J. 2020. PMID: 32031601 No abstract available.
-
Comments on the 2019 ESC/EAS guidelines for the management of dyslipidemias.Rev Esp Cardiol (Engl Ed). 2020 May;73(5):348-353. doi: 10.1016/j.rec.2019.11.019. Epub 2020 Mar 21. Rev Esp Cardiol (Engl Ed). 2020. PMID: 32205101 English, Spanish. No abstract available.
-
Targeting LDL cholesterol: Early treatment is key to population health.Atherosclerosis. 2020 May;300:37-38. doi: 10.1016/j.atherosclerosis.2020.03.013. Epub 2020 Mar 31. Atherosclerosis. 2020. PMID: 32253009 No abstract available.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical